Therapeutics Acquisition Corp (RACA)

Etorro trading 970x250
Therapeutics Acquisition Corp (RACA) Logo

About Therapeutics Acquisition Corp

Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts. Address: 200 Berkeley Street, Boston, MA, United States, 02116

Therapeutics Acquisition Corp News and around…

Latest news about Therapeutics Acquisition Corp (RACA) common stock and company :

Radio Caca (RACA) And EverGrow Coin (EGC) The Stars of Binance Smart Chain
21 Nov, 2021 FinancialContent
Notable Insider Buys In The Past Week: Asana, Transocean, IPOS, SPACS And More
05 Jul, 2021 FinancialContent

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. A couple of ...

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
01 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
30 Jun, 2021 FinancialContent
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
09 Jun, 2021 FinancialContent

Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600) (as amended, the “Registration Statement”), relating to the previously announced business combination (the “Business Combination”) with POINT Biopharma Inc. (“POINT”), has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) and that it will commence mailing a definitive proxy statement/prospectus relating to the Special Meeting (the “Special Meeting”) of the Company’s stockholders to be held on June 29, 2021 in connection with the Business Combination. The proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business on June 4, 2021 (the “Record Date”). Notice of the Special Meeting will be mailed on or about June 9, 2021 to stockholders of record as of the Record Date.

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
04 Jun, 2021 FinancialContent

POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for chemotherapy.

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
01 Jun, 2021 FinancialContent

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.

Therapeutics Acquisition Enters Oversold Territory (RACA)
12 Apr, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

SPACs Attack Weekly Recap: Looking Back On 7 Deals, Rumors And Headline News
21 Mar, 2021 FinancialContent

It was another busy week for the SPAC market with numerous deal announcements and rumored deals. Benzinga's "Spacs Attack" ...

Therapeutics Acquisition Becomes Oversold (RACA)
19 Mar, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
15 Mar, 2021 FinancialContent
Stocks That Hit 52-Week Lows On Thursday
04 Mar, 2021 FinancialContent

Thursday morning, 61 companies reached new 52-week lows. Areas of Significance: The largest company in ...

94 Biggest Movers From Yesterday
11 Feb, 2021 FinancialContent

Gainers Anchiano Therapeutics Ltd. (NASDAQ: ANCN) jumped 187.4% to close at $7.96. Bio-Path Holdings, Inc. (NASDAQ: BPTH) ...

Cerevance Appoints David Lubner to Board of Directors
08 Dec, 2020 FinancialContent

Life sciences industry veteran brings more than 25 years of financial and operational experience

Therapeutics Acquisition Corp (RACA) is a NASDAQ Common Stock listed in , ,

970x250